The test have been carried out by Cannabics Pharmaceuticals at the company’s High Through-put Screening (HTS) facility in Israel. The tests have shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumour properties after being tested on human Gastrointestinal Cancer Cells.
CBC and CBG
CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring phyto-cannabinoids, bearing a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities.
In these tests, the HTS platform was utilised to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested.
Hemp Oil Capsules
CBD Capsules 25 mg 30 count
CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.
Dr Yaakov Waksman, the company’s head of cannabidiol research, said: “My working assumption is that these results show that a correlation may exist between a cannabinoid’s Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumour activity, diminishing cancer cell’s viability rates.
“CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumour activity rates demonstrated”.
Dr Eyal Ballan, CTO and Co-Founder, added: “Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumour properties of cannabinoids.
“We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”